l nbdnj allosteric chaperone for multiple defective enzymes involved in lysosomal storage disorders lsds

Original title: “l-NBDNJ allosteric chaperone for multiple defective enzymes involved in lysosomal storage disorders (LSDs).”

caregiver reports of neurodevelopmental functions in pediatric lysosomal storage disorders a scoping review

Original title: “Caregiver Reports of Neurodevelopmental Functions in Pediatric Lysosomal Storage Disorders: A Scoping Review.”

PARAMUS, NJ - Polaryx Therapeutics , a clinical-stage biotechnology company developing novel, disease-modifying therapies for rare, pediatric lysosomal storage disorders , joins the global rare... The National Organization for Rare Diseases (NORD), a rare disease patient advocacy organization, notes that a disease is considered rare when it affects fewer than 1 in 2,000 people globally, with approximately 70% of these diseases starting in childhood. There are more than 6,000 rare diseases identified, 72% of which are genetically inherited. 'On Rare Disease Day, Polaryx proudly stands alongside the rare disease community - patients, families, caregivers, researchers, and advocacy partners to underscore the urgent need for new and transformative treatments,' said Polaryx Therapeutics (Nasdaq: PLYX), a clinical-stage biotechnology company developing novel, disease-modifying therapies for rare, pediatric lysosomal storage disorders ('LSDs'), joins the global rare disease community in raising awareness and supporting patients, families, caregivers, and healthcare providers. Rare Disease Day, observed annually on the last day of February, serves as an international campaign to raise awareness about the challenges faced by individuals and families living with rare diseases. ... SOTERIA is a Phase 2, open-label, single arm trial intended to assess the safety, tolerability, and clinical activity of Polaryx's lead drug candidate, PLX-200, in CLN2, CLN3, Krabbe disease, and Sandhoff disease, four different LSDs whose patient populations Polaryx believes represent approximately one quarter of the LSD population.

Original title: “Polaryx Therapeutics Marks Rare Disease Day, Reaffirming Commitment to Patients with Rare Pediatric Lysosomal Storage Disorders | MarketScreener India”

PARAMUS, NJ, Feb. 27, 2026 (GLOBE NEWSWIRE) -- Polaryx Therapeutics (Nasdaq: PLYX), a clinical-stage biotechnology company developing novel,... The National Organization for Rare Diseases (NORD), a rare disease patient advocacy organization, notes that a disease is considered rare when it affects fewer than 1 in 2,000 people globally, with approximately 70% of these diseases starting in childhood. There are more than 6,000 rare diseases identified, 72% of which are genetically inherited. “On Rare Disease Day, Polaryx proudly stands alongside the rare disease community - patients, families, caregivers, researchers, and advocacy partners to underscore the urgent need for new and transformative treatments,” said Alex Yang, Chairman and Chief Executive Officer of Polaryx Therapeutics, Inc. For more information about Rare Disease Day, please visit www.rarediseaseday.org. ... SOTERIA is a Phase 2, open-label, single arm trial intended to assess the safety, tolerability, and clinical activity of Polaryx’s lead drug candidate, PLX-200, in CLN2, CLN3, Krabbe disease, and Sandhoff disease, four different LSDs whose patient populations Polaryx believes represent approximately one quarter of the LSD population. A natural history study is a preplanned observational study intended to track the course of the disease. Should the data demonstrate compelling clinical activity, Polaryx may seek conditional marketing authorization. ... Polaryx Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing patient-friendly small molecule and gene therapy treatments for rare orphan lysosomal storage disorders (LSDs).

Original title: “Polaryx Therapeutics Marks Rare Disease Day, Reaffirming Commitment to Patients with Rare Pediatric Lysosomal Storage Disorders”

These results are a significant step forward as Polaryx Therapeutics prepares for a Phase 2 trial to further evaluate PLX-200. This article was generated with the support of AI and reviewed by an editor. For more information see our T&C. Polaryx selects CRO for phase 2 trial of rare disease treatment... Polaryx, a clinical-stage biotechnology company focused on developing treatments for rare pediatric lysosomal storage disorders, completed its initial public offering earlier this year. In other recent news, Polaryx Therapeutics has announced preclinical data regarding its drug candidate PLX-200, a reformulated version of gemfibrozil. (NASDAQ:PLYX) announced Tuesday it has selected a contract research organization (CRO) to conduct SOTERIA, a phase 2 trial evaluating its lead candidate PLX-200 across four rare lysosomal storage disorders (LSDs). The announcement comes as PLYX shares have experienced significant volatility, currently trading at $2.41, down 46.44% over the past week. The open-label, single-arm trial will assess PLX-200’s safety, tolerability, and clinical activity in patients with CLN2, CLN3, Krabbe disease, and Sandhoff disease - conditions that Polaryx estimates represent approximately one quarter of the LSD population. "Our selection of a CRO partner marks an important milestone for us as we continue to advance the clinical development of SOTERIA and move closer to the clinic," said Lisa Bollinger, Chief Medical Officer of Polaryx, in a press release statement. The company received a safe-to-proceed letter from the FDA in October 2025 and plans to initiate the trial in the first half of 2026 at sites in the United States, Europe, and potentially Asia. PLX-200 is an orally available compound comprised of gemfibrozil, an FDA-approved lipid regulating agent. According to the company, gemfibrozil’s ability to cross the blood-brain barrier has been documented in preclinical trials, which could be significant for treating these neurological disorders.

Original title: “Polaryx selects CRO for phase 2 trial of rare disease treatment By Investing.com”

These results are a significant step forward as Polaryx Therapeutics prepares for a Phase 2 trial to further evaluate PLX-200. This article was generated with the support of AI and reviewed by an editor. For more information see our T&C. Polaryx selects CRO for phase 2 trial of rare disease treatment... Polaryx, a clinical-stage biotechnology company focused on developing treatments for rare pediatric lysosomal storage disorders, completed its initial public offering earlier this year. In other recent news, Polaryx Therapeutics has announced preclinical data regarding its drug candidate PLX-200, a reformulated version of gemfibrozil. (NASDAQ:PLYX) announced Tuesday it has selected a contract research organization (CRO) to conduct SOTERIA, a phase 2 trial evaluating its lead candidate PLX-200 across four rare lysosomal storage disorders (LSDs). The announcement comes as PLYX shares have experienced significant volatility, currently trading at $2.41, down 46.44% over the past week. The open-label, single-arm trial will assess PLX-200’s safety, tolerability, and clinical activity in patients with CLN2, CLN3, Krabbe disease, and Sandhoff disease - conditions that Polaryx estimates represent approximately one quarter of the LSD population. "Our selection of a CRO partner marks an important milestone for us as we continue to advance the clinical development of SOTERIA and move closer to the clinic," said Lisa Bollinger, Chief Medical Officer of Polaryx, in a press release statement. The company received a safe-to-proceed letter from the FDA in October 2025 and plans to initiate the trial in the first half of 2026 at sites in the United States, Europe, and potentially Asia. PLX-200 is an orally available compound comprised of gemfibrozil, an FDA-approved lipid regulating agent. According to the company, gemfibrozil’s ability to cross the blood-brain barrier has been documented in preclinical trials, which could be significant for treating these neurological disorders.

Original title: “Polaryx selects CRO for phase 2 trial of rare disease treatment By Investing.com”

digital health for rare diseases a scoping review of artificial intelligence connected care and enabling digital technologies for lysosomal storage disorders

Original title: “Digital Health for Rare Diseases: A Scoping Review of Artificial Intelligence, Connected Care, and Enabling Digital Technologies for Lysosomal Storage Disorders.”